What is Barth syndrome?

Barth syndrome (BTHS) is a sporadic X-linked genetic disorder characterised by a myriad of clinical features including cardiomyopathy (a condition where the heart could become enlarged and fail to pump blood effectively), skeletal muscle weakness, neutropenia (a low count of neutrophils, a type of white blood cell), growth delays, and increased levels of 3-methylglutaconic acid in the urine.¹ This condition was named after Dr Peter Barth, who first described it in 1983. Barth syndrome primarily affects males, due to its inheritance pattern.² The disorder results from mutations (changes) in the TAZ gene (also known as G4.5), which is vital for the proper function of cardiolipin, a lipid essential for mitochondrial function (energy production in our cells).

Barth syndrome is a very rare disease, with fewer than 200 cases reported worldwide.³ The exact prevalence is difficult to determine due to underdiagnosis and misdiagnosis. However, it is estimated to affect approximately 1 in 300,000 to 400,000 live births.⁴ Most known cases are found in the United States, Europe, and Japan, though this may reflect regional differences in diagnostic capabilities and awareness rather than true geographic variation in incidence.

What are the causes and genetics?

Barth syndrome is mainly caused due to the mutational changes in the TAZ gene present on the X chromosome.⁵ The TAZ gene encodes the tafazzin protein, which is crucial for the remodelling of cardiolipin, a phospholipid that plays a key role in mitochondrial membrane integrity and function. Mutations in the TAZ gene lead to defective cardiolipin remodelling, resulting in impaired mitochondrial function. Since Barth syndrome is X-linked, it predominantly affects people assigned male at birth (AMAB), who have only one X chromosome. People assigned female at birth (AFAB) can be carriers and may exhibit mild symptoms due to X-chromosome inactivation patterns.

Cardiolipin is essential for the structural integrity and function of mitochondrial membranes. Dysfunctional mitochondria result in impaired energy production, contributing to the multisystemic manifestations of Barth syndrome. The major tissues in the body that are affected are the cardiac and skeletal muscles, along with the neutrophil cells which are important in the immune system.

What are the signs and symptoms associated with Barth syndrome?

The clinical presentation of Barth syndrome can be highly variable, even among affected members of the same family. Common signs and symptoms include:

• Cardiomyopathy: Dilated cardiomyopathy is the most prevalent cardiac manifestation, which can present in infancy or later in childhood. It often leads to heart failure and arrhythmias
• Skeletal Muscle Weakness: Generalised muscle weakness and exercise intolerance are typical
• Neutropenia: Chronic or intermittent neutropenia increases susceptibility to bacterial infections
• Growth Retardation: Delayed growth and failure to thrive are frequently observed
• Metabolic Abnormalities: Elevated levels of 3-methylglutaconic acid are a hallmark biochemical feature

How is Barth syndrome diagnosed?

Diagnosing Barth syndrome can be complex due to the rarity of the condition and the variability of its symptoms. A detailed diagnosis involves a combination of clinical evaluations, laboratory tests, genetic testing, and specialised diagnostic tools

Clinical Evaluation

Patient History and Physical Examination

1. Patient History: A detailed medical history is important. This includes documenting symptoms such as muscle weakness, growth delays, frequent infections, and any family history of similar symptoms or confirmed Barth syndrome
2. Physical Examination: The doctor conducts a thorough physical examination to identify signs like cardiomyopathy (enlarged heart), muscle hypotonia (reduced muscle tone), and other physical anomalies indicative of Barth syndrome

Laboratory Tests

Blood Tests

1. Complete Blood Count (CBC): Neutropenia (low neutrophil count) is a key indicator of Barth syndrome.
2. Blood Chemistry Tests: These tests measure levels of various chemicals in the blood, providing information about organ function and identifying metabolic anomalies.
3. Organic Acid Screening: Urine tests can detect elevated levels of specific organic acids (such as 3-methylglutaconic acid), which are often higher in individuals with Barth syndrome.

Cardiac Evaluations

1. Echocardiogram: An ultrasound of the heart to check for cardiomyopathy, structural abnormalities, and how well the heart pumps blood
2. Electrocardiogram (ECG): Measures the electrical activity of the heart to detect arrhythmias and other abnormalities

Neutrophil Function Tests

1. Absolute Neutrophil Count (ANC): Repeated measurements of ANC to monitor neutrophil levels and assess the severity and pattern of neutropenia.
2. Neutrophil Function Tests: These tests assess how well neutrophils respond to infections.

Genetic Testing- TAZ Gene Sequencing

1. DNA Sequencing: Genetic testing is the definitive method for diagnosing Barth syndrome. A blood or saliva sample is taken to analyse the TAZ gene for mutations.
2. Carrier Testing: For family members to determine if they carry the mutated TAZ gene, even if they do not exhibit symptoms.

Specialised Diagnostic Tools

Metabolic Tests

1. Cardiolipin Analysis: This test measures cardiolipin levels and structure in cells, often revealing abnormalities characteristic of the syndrome
2. Mass Spectrometry: Advanced techniques like mass spectrometry can identify and quantify abnormal organic acids and other metabolic markers associated with Barth syndrome

Diagnostic Criteria

1. Cardiomyopathy: Presence of dilated heart or other heart problems.
2. Neutropenia: Persistent or intermittent low neutrophil counts.
3. Growth Retardation: Delayed growth patterns in children.
4. Metabolic Abnormalities: Elevated levels of 3-methylglutaconic acid in urine.
5. Genetic Confirmation: Mutation in the TAZ gene is confirmed through genetic testing.

Challenges in Diagnosis

Rarity and Variability

1. Rarity: Barth syndrome is extremely rare, with fewer than 200 known cases worldwide. This could lead to misdiagnosis
2. Variability: Symptoms can vary widely among individuals, even within the same family. This variability can complicate the clinical recognition of the syndrome

Overlapping Symptoms

Many symptoms of Barth syndrome overlap with other more common conditions, such as other forms of cardiomyopathy, primary neutropenia disorders, and metabolic syndromes, making differential diagnosis essential.

Diagnostic Delays

Due to its complexity and rarity, there may be significant delays in reaching a diagnosis. This can impact early intervention and management, highlighting the need for awareness and expertise among healthcare providers.

How is Barth syndrome treated?

Multidisciplinary Approach

The management of Barth syndrome requires a multidisciplinary approach, involving cardiologists, hematologists, geneticists, endocrinologists, nutritionists, and physical therapists. Treatment is largely supportive and symptomatic, aimed at addressing the specific clinical manifestations in each patient.

Cardiac Management

1. Medications: Standard heart failure medications, including angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics, are used to manage cardiomyopathy
2. Device Therapy: Implantable cardioverter-defibrillators (ICDs) or pacemakers may be necessary for patients with life-threatening arrhythmias
3. Heart Transplantation: In severe cases, where medical management fails, heart transplantation may be considered. However, this option is limited by donor availability and the patient’s overall health status

Hematological Management

1. Infection Prevention: Prophylactic antibiotics and granulocyte colony-stimulating factor (G-CSF) can be used to manage neutropenia and prevent infections
2. Immunisations: Ensuring that patients are up-to-date with vaccinations, especially against encapsulated organisms, is crucial

Growth and Nutrition

1. Nutritional Support: A balanced diet with adequate caloric intake is essential for growth. Nutritional supplements and feeding tubes may be required in cases of severe failure to thrive
2. Growth Hormone Therapy: Although controversial, growth hormone therapy can be considered for children with significant growth delays, under careful monitoring

Metabolic Management

1. L-Carnitine Supplementation: Some studies suggest that L-carnitine supplementation may help improve muscle function, though its efficacy remains to be conclusively proven
2. Mitochondrial-targeted Therapies: Emerging therapies targeting mitochondrial function, such as elamipretide, are being investigated in clinical trials

Physical Therapy

1. Exercise Programs: Tailored physical therapy and exercise programs can help improve muscle strength and endurance, although caution is necessary to avoid exacerbating cardiac issues
2. Occupational Therapy: Occupational therapy can assist in improving daily functioning and quality of life

Research and Emerging Therapies

Ongoing research aims to better understand the pathophysiology of Barth syndrome and develop targeted treatments. Key areas of investigation include:

1. Gene Therapy: Gene therapy approaches aim to correct the underlying genetic defect by delivering a functional copy of the TAZ gene to affected cells⁶
2. Stem Cell Therapy: Stem cell therapy is being explored as a potential treatment to regenerate damaged cardiac and skeletal muscle tissue
3. Drug Development: Several compounds targeting mitochondrial function and cardiolipin remodelling are under investigation

Conclusion

Barth syndrome is a complex, multisystem disorder requiring comprehensive management and ongoing research to improve outcomes. Early diagnosis through genetic testing and a multidisciplinary approach to treatment can significantly enhance the quality of life for affected individuals. While current treatments are primarily supportive, advances in genetic and molecular therapies hold promise for more targeted and effective interventions in the future. Collaborative efforts among researchers, clinicians, and patient advocacy groups are essential to drive progress in understanding and managing this rare but impactful disorder.